AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that Dr. Scott T. Tagawa, M.D., M.S., FACP, a Professor of Medicine and Urology at Weill Cornell Medicine and an Attending Physician at New York-Presbyterian-Weill Cornell Medical Center, has joined the Company’s Scientific Advisory Board. (PRNewsfoto/AIkido Pharma Incorporated) “Scott is a leading scholar in the field of oncology medicine and research,” commented Mr. Anthony Hayes, CEO of AIkido. “His experience and expertise will be of tremendous value as we further our efforts to develop therapeutic treatments for cancer and leverage the technologies we have licensed. Dr. Tagawa is also the principle investigator for the targeted radiopharmaceutical therapy at Weil Cornell and his addition to our advisory board demonstrates our support for this innovative technology.” Dr. Scott T. Tagawa, MD, MS, FACP is a Professor of Medicine & Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center. Dr. Tagawa earned his BS from Georgetown University. He received his MD at the University of Southern California School of Medicine and after completing his internship and residency training there, he became Chief Resident. Subsequently, he underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two   Read more…

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that Dr. Neil H. Bander, M.D., a physician-researcher at Weill Cornell Medicine, has joined the Company’s Scientific Advisory Board. (PRNewsfoto/AIkido Pharma Incorporated) “Dr. Bander heads one of the world’s most experienced and accomplished teams in antibody-targeted therapy of prostate cancer at Cornell University and is a widely respected inventor of patented technologies and recognized expert in the field of urological oncology,” commented Mr. Anthony Hayes, CEO of AIkido. “Importantly, Dr. Bander is the inventor of targeted radiopharmaceutical therapy technology at Convergent Therapeutics, Inc. which we are proud to support. We are honored to have him join our team of advisors and work more directly in our efforts to advance the development of this technology.”   “Using his clinical background and laboratory efforts, Dr. Bander has exemplified the role of surgeon-scientist,” added Mr. Hayes. “His research has spawned novel clinical trials that are unique in urological oncology and have already made a difference in the lives of prostate cancer patients. We look forward to leveraging his expertise as we continue to develop our platforms and forge a path towards the treatment of cancer.” Dr. Bander, M.D. completed fellowship training in both tumor immunology   Read more…

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company executed a Two Million Dollar Convertible Promissory Note Purchase Agreement with Convergent Therapeutics, Inc., securing an early investment in Convergent. Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. and foreign patents. Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy (“PRRT”) that targets the prostate-specific membrane antigen (“PSMA”) present on prostate cancer cells. The technology was developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.   The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-α, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter. The function of CONV 01-α is unique in that it not only binds specifically to the PSMA receptor on prostate cancer cells, but also stimulates the internalization of the receptor along with itself and its powerful radioactive payload directly into tumor cells. Convergent is presently conducting two sets of human clinical trials using CONV 01-α as a single agent treatment for prostate cancer. The first is a Phase 1a/2a   Read more…

SAN DIEGO, July 15, 2020 AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, today announced the development of NeuCovixTM, a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovixTM differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes. “We are hopeful our test fills an important need in these uncertain times. While other tests merely show whether someone was infected with coronavirus, we took it a step further by creating a test that stratifies individuals into those who have neutralizing antibodies, which are essential in preventing reinfection, and those who don’t. The test can be deployed for point of care use in convalescent plasma transfusions to severely ill patients and for evaluating efficacy of upcoming vaccines in generating protective antibodies,” said Sergei Svarovsky, PhD, MBA, AXIM’s   Read more…

Kempten, Bavaria (Findit) June 27, 2019 – From June 4th to 6th of 2019, “SNEC2019 International Solar Photovoltaic and Smart Energy (Shanghai) Exhibition and Conference” was successfully held in Shanghai, China. Kipp & Zonen, known for its leading solar radiation measurement instruments, exhibited at SNEC and presented its innovative new product DustIQ for soiling measurement to the “SNEC Top 10 Highlights” selection committee. Kipp & Zonen and the Chinese Meteorology team of OTT HydroMet are proud to inform that DustIQ won the Megawatt Jadeite Award. Caption: KIPP & ZONEN’s DUSTIQ wins the Megawatt Jadeite Award The “SNEC Top 10 Highlights” awards started in 2011 and have been held for the ninth time this year. This selection event is an affirmation of the cutting-edge technology and products of exhibitors. The “Top 10 Highlights” awards have four awards, namely the Terawatt Diamond Award, Gigawatt Gold Award, Megawatt Jadeite Award, and Honorary Award. After professional review by experts, the new soiling monitoring system DustIQ won the Megawatt Jadeite Award. On behalf of Kipp & Zonen, Leo Teng, technical manager at OTT HydroMet in China, accepted the trophy and certificate granted by the organizing committee. “It not only represents the honor but also shows   Read more…

Apple will finally introduce IOS 13 for iPhones, a major software upgrade that will hopefully fix some of the annoyances that iPhone X, XS, XR and XS Max users experience when using the phone. Major IOS launches typically happen before the release of a new iPhone and if Apple sticks to their typical plan, we should see a new iPhone launch in the Mid-September time frame. For many, with the all screen design, one-handed use of the iPhone X, XS, XS Max and so on becomes clunky or even down-right difficult. Once you add a screen protector on the front and a suitable case to protect the glass in the back, you have a much thicker phone which makes using it one-handed even that much more difficult. An IOS 13 concept hopes to change that. Designer Maximos Angelakis has come up with a way to have a much more user-friendly experience when using the iPhone X (and the newer versions) with one hand. By shrinking down the user-interface and bringing it closer to the thumb, users should be able to control what you are doing with the phone much easier. The new concept features pop-ups and buttons as well as   Read more…

Montreal, Canada (findit) May 18, 2019 – Future Lighting Solutions is very pleased to announce that they will be participating in the 30th edition of LIGHTFAIR from May 21-23, 2019 at the Pennsylvania Convention Center in Philadelphia. LIGHTFAIR International is the world’s most important architectural and commercial lighting conference, where light, technology, knowledge and design connect in a convergence of global introductions, innovations and thought leadership. This year’s theme is The Synergy of Light in Life, and FLS’ booth #1349 will feature horticulture lighting, human centric lighting, UV LED technology for water/surface/air purification, qualified Bluetooth mesh lighting control technology and the introduction of FLS’ first mobile App for iOS and Android. “LIGHTFAIR 2019 provides a unique opportunity to showcase exactly how our customers develop innovative solid state lighting fixtures by leveraging FLS’ industry leading product portfolio, best-in-class technical resources, and global supply chain solutions,” said Larry Posivak, Vice President of Sales at Future Lighting Solutions. “Our system-level approach provides customers the ability to accelerate their time-to-market across the entire range of LED lighting applications.” FLS will also be presenting a highly-anticipated workshop, Growth Strategies for Existing and Emerging Lighting Applications, on Sunday, May 19. The Growth Strategies workshop will be   Read more…

Kempten, Bavaria (findit) May 17, 2019 – A new generation of remote-controlled, ultra-low-power dataloggers for agricultural, meteorological and hydrological applications is now available from OTT HydroMet. The ADCON SERIES 6 RTU differentiates from its predecessors by a self-monitoring battery, a larger memory for up to 2 million values and its convenient firmware update over the air as well as the future-proof design for integration in IoT networks and existing state-of-the-art communication technologies. The new series comes in three different models: the A760, the A764 and the A765. They differ in the number of connectors and are available as 2G/3G or 4G/LTE version. With their 32-bit CPU, they deliver the data quickly and reliably. Further advantages are the data encryption option to ensure data safety and the wireless communication via Bluetooth for field maintenance purpose. Together with the addVANTAGE Pro software, the dataloggers form an integrated system solution. ADCON’S NEXT GENERATION: NO DATA GAP SOLUTION The innovative series of data loggers from the ADCON SERIES 6 RTU is fast, relible, rugged and durable. It was developed for agricultural, meteorological and hydrological applications. The measuring instruments allow convenient, flexible remote control so that maintenance and sensor analysis are simplified, leading to a   Read more…

DHEA, is an acronym for dehydroepiandrosterone; a naturally occurring pro-hormone produced by the adrenal glands, gonads and the skin – the dermis. DHEA is a base building block for hormones like testosterone and estrogen and about 50 other hormones. DHEA is the most abundant prohormone in the body. Hormones drive our energy, mood, muscle tone, fat, quality of sleep, mental sharpness, sex drive, and more. What happens to DHEA over the course of a human life? Humans produce more and more DHEA from birth through puberty to adulthood, when we are in our reproductive prime as humans.  But after about age 25 males and females alike make about 2% less each year for the rest of our lives   So, if DHEA levels are a base for hormones, and DHEA levels decline steadily after  age 25 at a rate of 2% per year, by age 35 people make about 20% less than they did at age 25, when at their best, or at their prime. By age 50 people make only half as much. Why does this matter? What are some things DHEA does? Men and women notice the gradual declines in hormones in many small subtle declines after about   Read more…

PACKETOP, a leading provider of network analytics data automation and network optimization located in Naperville, IL, today announced that it has been acquired by MTechnologies, GMBH a leading provider of enterprise software solutions based in Zug, Switzerland in an all-cash transaction. Pursuant to the terms of the merger agreement, MTechnologies. (together with its affiliate, 3M Holding company, AG, an investment firm) purchased all of the outstanding shares of the PACKETOP in an all-cash transaction. PACKETOP Board of Directors unanimously approved the agreement and believes the transaction maximizes shareholder value. It will also bring a better support and presence for their new customers, Mobiitie & P&G. Following the execution of the merger agreement, “MTechnologies announced that Adam Maghrouri will continue as the president of PACKETOP. Adam Maghrouri brings 20 years of successful experience in the Information Technology field, we will rely on his total discretion as the direction of PACKETOP in Americas”, said Ivo Szakolczai president of MTechnologies. Today’s announcement is a tremendous accomplishment for MTechnologies and highlights the continued success of the Company & foothold in the US market, continued Ivo Szakolczai. PACKETOP will be relocating to Northern Virginia area, moving closer to the technology corridor & their customers.